These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 7576915)

  • 21. Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.
    Warren RQ; Anderson SA; Nkya WM; Shao JF; Hendrix CW; Melcher GP; Redfield RR; Kennedy RC
    J Virol; 1992 Sep; 66(9):5210-5. PubMed ID: 1380094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High antigenic cross-reactivity of the V3 consensus sequences of HIV-1 gp120.
    Baillou A; Brand D; Denis F; M'Boup S; Chout R; Goudeau A; Barin F
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1209-15. PubMed ID: 7511395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV type 1 V3 serotyping of Tanzanian samples: probable reasons for mismatching with genetic subtyping.
    Hoelscher M; Hanker S; Barin F; Cheingsong-Popov R; Dietrich U; Jordan-Harder B; Olaleye D; Nägele E; Markuzzi A; Mwakagile D; Minja F; Weber J; Gürtler L; Von Sonnenburg F
    AIDS Res Hum Retroviruses; 1998 Jan; 14(2):139-49. PubMed ID: 9462924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seroreactivity to HIV-1 V3 subtypes A to H peptides of Argentinian HIV-positive sera.
    Devito C; Levi M; Hinkula J; Fernandez Medina RD; Libonatti O; Wigzell H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Feb; 17(2):156-9. PubMed ID: 9473017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization.
    Louisirirotchanakul S; Beddows S; Cheingsong-Popov R; Shaffer N; Mastro TD; Auewarakul P; Likanonsakul S; Wasi C; Weber J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):315-20. PubMed ID: 9833739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120.
    Boudet F; Girard M; Theze J; Zouali M
    Int Immunol; 1992 Feb; 4(2):283-94. PubMed ID: 1377948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
    Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
    J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between anti-V3 peptide and neutralizing antibodies in plasma from HIV-1 infected individuals resident in Brazil.
    Bongertz V; Morgado MG; Galvão-Castro B; Wigzell H; Hendry RM
    Mem Inst Oswaldo Cruz; 1994; 89(1):113-4. PubMed ID: 7823807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodies.
    Polonis VR; De Souza MS; Chanbancherd P; Chantakulkij S; Jugsudee A; Loomis-Price LD; Vancott TC; Garner R; Markowitz LE; Brown AE; Birx DL
    AIDS Res Hum Retroviruses; 2001 Jan; 17(1):69-79. PubMed ID: 11177385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The antigenic tip GPGRAFY of the V3 loop on HIV-1 gp120: genetic variability and subtypes.
    Dong XN; Wu Y; Ying J; Chen YH
    Immunol Lett; 2005 Oct; 101(1):112-4. PubMed ID: 15913789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic, antigenic and serologic characterization of human immunodeficiency virus type 1 from Indonesia.
    Porter KR; Mascola JR; Hupudio H; Ewing D; VanCott TC; Anthony RL; Corwin AL; Widodo S; Ertono S; McCutchan FE; Burke DS; Hayes CG; Wignall FS; Graham RR
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Jan; 14(1):1-6. PubMed ID: 8989203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-reactivity between autoimmune anti-U1 snRNP antibodies and neutralizing epitopes of HIV-1 gp120/41.
    Douvas A; Takehana Y
    AIDS Res Hum Retroviruses; 1994 Mar; 10(3):253-62. PubMed ID: 7517148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antigenic and immunogenic sites of HIV-2 glycoproteins.
    Chiodi F; Björling E; Samuelsson A; Norrby E
    Chem Immunol; 1993; 56():61-77. PubMed ID: 8452654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristic of HIV-1 in V3 loop region based on seroreactivity and amino acid sequences in Thailand.
    Balachandra K; Matsuo K; Sutthent R; Hoisanka N; Boonsarthorn N; Sawanpanyalert P; Warachit P; Yamazaki S; Honda M
    Asian Pac J Allergy Immunol; 2002 Jun; 20(2):93-8. PubMed ID: 12403193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1 V3 loop crown epitope-focused mimotope selection by patient serum from random phage display libraries: implications for the epitope structural features.
    Gazarian KG; Palacios-Rodríguez Y; Gazarian TG; Huerta L
    Mol Immunol; 2013 Jun; 54(2):148-56. PubMed ID: 23270686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
    Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
    Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.